ANXA2 (annexin A2) is crucial to ATG7-mediated autophagy, leading to tumor aggressiveness in triple-negative breast cancer cells
Minsoo KohHyesol LimHao JinMinjoo KimYeji HongYoung Keun HwangYunjung WooEun-Sook KimSun Young KimKyung Mee KimHyun Kyung LimJoohee JungSujin KangBoyoun ParkHan-Byoel LeeWonshik HanMyung-Shik LeeAree Moona Duksung Innovative Drug Center,College of Pharmacy,Duksung Women's University,Seoul,Koreab Department of Systems Biology,College of Life Science and Biotechnology,Yonsei University,Seoul,South Koreac Department of Chemistry,College of Science and Technology,Duksung Women's University,Seoul,Koread Department of Surgery,Seoul National University College of Medicine,Seoul,Koreae Cancer Research Institute,Seoul National University College of Medicine,Seoul,Koreaf Avison Biomedical Research Center,Yonsei University College of Medicine,Seoul,Korea
DOI: https://doi.org/10.1080/15548627.2024.2305063
IF: 13.391
2024-01-31
Autophagy
Abstract:Triple-negative breast cancer (TNBC) is associated with a poor prognosis and metastatic growth. TNBC cells frequently undergo macroautophagy/autophagy, contributing to tumor progression and chemotherapeutic resistance. ANXA2 (annexin A2), a potential therapeutic target for TNBC, has been reported to stimulate autophagy. In this study, we investigated the role of ANXA2 in autophagic processes in TNBC cells. TNBC patients exhibited high levels of ANXA2, which correlated with poor outcomes. ANXA2 increased LC3B-II levels following bafilomycin A 1 treatment and enhanced autophagic flux in TNBC cells. Notably, ANXA2 upregulated the phosphorylation of HSF1 (heat shock transcription factor 1), resulting in the transcriptional activation of ATG7 (autophagy related 7). The mechanistic target of rapamycin kinase complex 2 (MTORC2) played an important role in ANXA2-mediated ATG7 transcription by HSF1. MTORC2 did not affect the mRNA level of ANXA2 , but it was involved in the protein stability of ANXA2. HSPA (heat shock protein family A (Hsp70)) was a potential interacting protein with ANXA2, which may protect ANXA2 from lysosomal proteolysis. ANXA2 knockdown significantly increased sensitivity to doxorubicin, the first-line chemotherapeutic regimen for TNBC treatment, suggesting that the inhibition of autophagy by ANXA2 knockdown may overcome doxorubicin resistance. In a TNBC xenograft mouse model, we demonstrated that ANXA2 knockdown combined with doxorubicin administration significantly inhibited tumor growth compared to doxorubicin treatment alone, offering a promising avenue to enhance the effectiveness of chemotherapy. In summary, our study elucidated the molecular mechanism by which ANXA2 modulates autophagy, suggesting a potential therapeutic approach for TNBC treatment. Abbreviation: ATG: autophagy related; ChIP: chromatin-immunoprecipitation; HBSS: Hanks' balanced salt solution; HSF1: heat shock transcription factor 1; MTOR: mechanistic target of rapamycin kinase; TNBC: triple-negative breast cancer; TFEB: transcription factor EB; TFE3: transcription factor binding to IGHM enhancer 3
cell biology